Pricing Log in Create free account

DiaMedica Therapeutics, Inc. (DMAC) vs Prothena Corporation plc (PRTA)

DiaMedica Therapeutics, Inc. and Prothena Corporation plc are both Biotechnology companies. DiaMedica Therapeutics, Inc. and Prothena Corporation plc are of similar size ($436.4M and $433.6M). DiaMedica Therapeutics, Inc. has the higher net margin (0.00% vs −80.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, DiaMedica Therapeutics, Inc. leads on 6 and Prothena Corporation plc on 6.

Valuation

Metric DMAC PRTA Biotechnology median
P/E n/m n/m 8.50
P/S n/m 7.98 9.71
P/B 10.68 1.52 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 2.70 9.21
Earnings yield (9.47%) (9.94%) (33.15%)
Free cash flow yield (7.70%) (13.96%) (25.50%)

Profitability

Metric DMAC PRTA Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (101.80%) 0.00%
Net margin 0.00% (80.67%) 0.00%
Free cash flow margin 0.00% (111.49%) 0.00%
Return on equity (114.62%) (14.39%) (56.36%)
Return on assets (98.18%) (12.54%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DMAC PRTA Biotechnology median
Revenue growth (TTM) — 427.32% 6.02%
EPS growth (last fiscal year) (16.67%) (99.56%) 30.26%
Revenue growth, 5-year CAGR — 62.56% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMAC PRTA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.72 25.05 4.72
Net debt to EBITDA 1.70 1.46 0.96

Dividend

Metric DMAC PRTA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DMAC PRTA Biotechnology median
Market cap 433.56m 436.36m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack